Akebia Therapeutics, Inc. - Common Stock (AKBA)
Competitors to Akebia Therapeutics, Inc. - Common Stock (AKBA)
Apexigen, Inc.
Apexigen, although primarily focused on developing therapies for cancer, also competes with Akebia in the broader biopharmaceutical landscape by attracting investors and partnerships. Apexigen's innovative approach to monoclonal antibodies could divert potential funding and interest away from Akebia’s renal-specific therapies. While their focus areas do not directly overlap, the competition lies in attracting similar investor sentiments and market stakeholders, thus creating a competitive environment for securing financial resources.
CRISPR Therapeutics AG CRSP -1.29%
CRISPR Therapeutics operates in a distinct space of gene editing, primarily focusing on genetic diseases; however, their innovative platforms also attract investment and public attention that could have otherwise been directed toward Akebia. While not in direct therapeutic competition, both companies vie for leading positions in innovative biotechnology, and CRISPR's pioneering work in gene editing could overshadow Akebia’s advancements in chronic kidney disease treatments, leveraging a strong technological edge in the market.
FibroGen, Inc. FGEN -4.72%
FibroGen, Inc. is a major competitor of Akebia Therapeutics in the field of treating anemia associated with chronic kidney disease. Both companies focus on developing therapies that endogenously stimulate erythropoiesis. FibroGen's lead product candidate, roxadustat, has gained traction in several markets, including China and is under review in the U.S. Akebia's lead product, vadadustat, offers similar mechanisms of action, but has faced regulatory challenges. Therefore, competition is fierce as both companies are vying for market share in the same niche, with FibroGen currently having a first-mover advantage in some regions.
NantHealth, Inc.
NantHealth focuses on its proprietary technology to improve patient outcomes, making it a relevant competitor to Akebia in terms of seeking partnerships with healthcare providers and pharmaceutical firms. While their primary focus is on personalized medicine, the competitive aspect stems from efforts to establish collaborations with stakeholders who might be interested in investing in or working with Akebia’s renal health therapeutics. NantHealth's technological advancements may attract similar partnerships that could benefit their operations more than Akebia’s, presenting an indirect competitive edge.